Procalcitonin Aided Antimicrobial Therapy vs Standard of Care

Antibiotic resistance is driven by overuse, especially for viral respiratory infections. Procalcitonin (PCT), a biomarker for bacterial infections, helps guide antibiotic therapy more precisely, reducing unnecessary use and improving outcomes. Studies, including large trials and economic models across several countries, show PCT-guided treatment lowers mortality, antibiotic exposure, therapy duration and related complications, potentially reducing hospital costs despite initial testing expenses.

NCT Number	NCT06960044
Lead Sponsor	Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria Collaborators: Thermo Fisher Scientific FS
Conditions	Lower Respiratory Tract Infection (LRTI)
Enrollment	108 participants
Start Date	2025-06-01
Primary Completion	2026-12-01 (estimated)
Study Completion	2027-06-01 (estimated)
Updated on ClinicalTrials.gov	2025-05-07